Key Findings
The North America Point of care diagnostic market was valued at $XX million in 2018 and is expected to reach $XX million by 2027 with a CAGR of 8.82% during the forecast period. The increase in healthcare spending mainly supports the growth of the market.

Market Insights
The growth in incidence and prevalence of diseases such as diabetes and cardiac disorders accompanied by the rise in the elderly population are some factors that majorly drive the POC diagnostic devices in North America. Increased awareness about innovative and advanced applications of POC diagnostic devices and well-established healthcare infrastructure also supports the growth of the point of care diagnostics market in North America. The United States and Canada is considered for market analysis.

Competitive Insights
The major companies operating in the market are Chembio Diagnost ICS Systems, Inc., Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd., Quest Diagnostics Inc., Danaher Corporation, Thermo Fisher Scientific Inc., Biom?rieux SA, Abbott, Cardinal Health Inc., Trivitron Healthcare, Becton Dickinson and Company, Gene POC, Siemens Healthineers, Ortho Clinical Diagnostics, Trinity Biotech, and Sight Diagnostics Ltd.